Zimmer Biomet Holdings Inc., a global leader in musculoskeletal healthcare, on Friday announced that Ivan Tornos has been appointed to the newly-created position of chief operating officer.
Tornos joined Zimmer Biomet in November 2018 as group president, orthopedics, and a year later was named group president, global businesses and the Americas. In this new role, he will continue to report directly to Bryan Hanson, president and CEO, and will be responsible for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and new product development functions, according to a news release from Zimmer Biomet.
In addition to his continued leadership of the Americas region, Tornos will now have oversight of the Europe, Middle East and Africa (EMEA) region, with the president of EMEA reporting directly to him.
“Since joining Zimmer Biomet, Ivan has made tremendous contributions toward the strategic evolution of our business, delivering consistent results across the board,” said Hanson. “As we continue to transform the company, having Ivan at the helm in this newly-created and expanded role to drive forward, align and execute on our operations helps ensure we continue to deliver for our customers, patients and shareholders.”
Prior to joining Zimmer Biomet, Tornos served as worldwide president of the Global Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Earlier, he was with C.R. Bard in positions of increasing responsibility, most recently serving as president, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Tornos served as vice president and general manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. He also served as international vice president, business development and strategy with Baxter International Inc., and prior to that he spent over a decade in leadership assignments around the globe with Johnson & Johnson.
Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and he also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business.
The company also announced Friday that Didier Deltort, who has served as the president of EMEA since August 2018, will be departing Zimmer Biomet for another professional appointment. A search is underway for a new president of the EMEA region. In the near-term, Deltort will continue to oversee marketing, sales and distribution of products, services and solutions in the EMEA region, partnering closely with Tornos.
“We wish Didier continued success in his next career endeavor,” said Hanson. “On behalf of the Zimmer Biomet team, I want to thank him for his strong and collaborative partnership over the last three years and for his commitment to ensuring a smooth and successful transition of his responsibilities.”
Founded in 1927 and headquartered in Warsaw, Zimmer Biomet is a global leader in musculoskeletal healthcare, the release states. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
